Sonia T. Oskouei, PharmD: Anticancer Biosimilars in 2019

December 16, 2019

Sonia T. Oskouei, PharmD, vice president of innovation and solution development at Premier Inc, discusses how anticancer biosimilars have played a role in oncology in 2019.

Transcript

I would say, right now, the oncology biosimilars in the therapeutic space is still new and limited. It's only been a few months since we've had the first 2 become available in the market that's not in supportive care.

Thus far, it's been, from at least a health system perspective, it's been a slower uptake and utilization. But part of that is because there is the awareness and increasing awareness from stakeholders about when additional products are going to be coming to market.

So for these oncology disease-modifying agents, there's an awareness that there's going to be additional ones coming out in the next few months. So instead of making a decision at the point in time when the first ones are launched, if you know there's going to be more coming out in the near future, a lot of health systems are waiting to see, okay, well, let's make that decision at that time to see what's going to be the most viable and financially positive for us to utilize.

Related Content:

Interviews | Oncology

x